FDA Approves Durvalumab for Muscle Invasive Bladder Cancer By Ogkologos - May 2, 2025 752 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR What to Know About Using Activated Charcoal During Cancer December 21, 2023 OncoArray Links Dozens of DNA Variants to Risk for Common Cancers June 12, 2018 Better together: improving brain tumour treatment February 13, 2023 Colposcopia: Cómo prepararse y qué saber August 6, 2020 Load more HOT NEWS TRACERx: Using blood tests to track lung cancer After Breast Cancer Diagnosis, Technology Professor Teaches Computers to Read Mammograms Gene Tied to Alzheimer’s May Be Associated with Cancer-Related Cognitive Problems First-Line Pembrolizumab Continues to Show Durable Clinical Benefit After 5 Years...
